Natural Gums, Resin Or Latex Patents (Class 424/485)
-
Publication number: 20110117196Abstract: The invention provides a novel solid pharmaceutical dosage form which includes an opiate, an opiate antagonist admixed with the analgetic (opiate agonist) and an amount of a hydrocolloid containing excipient which is effective to form a non-injectable slurry when the dosage form is contacted with water. In addition the dosage form contains pure naloxone in enteric coated form which is designed to release in the colon to prevent or relieve constipation. Thus the formulation, because of the enteric coated naloxone and the hydrocolloid excipient(s), has reduced side effects as compared with formulations which do not contain these features.Type: ApplicationFiled: January 18, 2011Publication date: May 19, 2011Inventor: Maxwell Gordon
-
Publication number: 20110104273Abstract: Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.Type: ApplicationFiled: November 5, 2010Publication date: May 5, 2011Applicant: DEPOMED, INC.Inventor: Sui Yuen Eddie Hou
-
Publication number: 20110097405Abstract: The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen.Type: ApplicationFiled: February 5, 2009Publication date: April 28, 2011Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Adrian Funke, Sascha General, Ildikó Terebesi, Christian Zurth, Sofia Alincic-kunz, Matthias Schäfer, Thomas Holler, Konstanze Diefenbach
-
Patent number: 7923035Abstract: The humidity-dependent antibacterial powdery composition comprises a volatile oily antibacterial substance contained in a high ratio and a water-soluble film forming agent and the behavior of release of the antibacterial substance is changed depending on humidity. The process for producing the same is characterized in that a water-soluble film forming agent optionally together with a powder vehicle is dissolved and/or dispersed in water, subsequently a volatile oily antibacterial substance optionally together with an emulsifying agent is added to the solution and emulsified, and thereafter the obtained emulsion is spray dried into powder. The humidity-dependent antibacterial food storing article is characterized by carrying the humidity-dependent antibacterial powdery composition. The method of storing food is characterized in that the volatile oily antibacterial substance is released from the humidity-dependent antibacterial food storing article toward food lying in an atmosphere of 70% or higher humidity.Type: GrantFiled: October 22, 2003Date of Patent: April 12, 2011Assignee: Mitsubishi-Kagaku Foods CorporationInventors: Shigeo Ii, Asami Takata, Yuichi Mizukami, Ikuo Yashiki
-
Publication number: 20110064810Abstract: The various embodiments herein relate to an injectable matrix used for regeneration, reconstruction, repair or replacement of organ or tissue. The injectable matrix consists of a synthetic and natural polymer, a stem cell niche and nanoparticles in the form of cups filled with growth factor and physiologic agent. The embodiments herein also provide a method for regeneration, reconstruction, repair or replacement of organ or tissue. In the method, an injectable matrix is injected to create three dimensional matrix system or network in an area of the desired tissue or organ, migration of blood circulatory stem cells or tissue-specific progenitor cells occur to the injected area of the tissue or organ. The growth factors and physiological agent present in the nanocups are released. The stem cells proliferate and differentiate to form the desired organ or tissue.Type: ApplicationFiled: November 18, 2010Publication date: March 17, 2011Inventor: Jalaledin Ghanavi
-
Publication number: 20110052699Abstract: A drug delivery system also intended as unit dosage form comprising a thin water-soluble film matrix, wherein said film matrix comprises a) a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer) as a water-soluble matrix polymer; an active ingredient being a steroid in which the positions 6 and 7 of the steroidal skeleton are both a —CH2— residue; and said film matrix has a thickness of less than 300 ?m.Type: ApplicationFiled: February 10, 2009Publication date: March 3, 2011Inventors: Adrian Funke, Ildiko Terebesi, Sascha General
-
Patent number: 7887842Abstract: Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.Type: GrantFiled: January 8, 2004Date of Patent: February 15, 2011Assignees: Teikoku Pharma USA, Inc., Teikoku Seiyaku Kabushiki KaishaInventors: John Koo, Jutaro Shudo, Sadanobu Shirai
-
Publication number: 20110027361Abstract: The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same.Type: ApplicationFiled: February 3, 2009Publication date: February 3, 2011Applicant: TORRENT PHARMACEUTICALS LTD.Inventors: Ganesan Murugesan, Jaya Abraham, Vinodkumar Gupta, Bhavesh Shah
-
Patent number: 7875212Abstract: Embodiments of the present invention provide polymer matrix nanocomposites reinforced with nano-scale materials such as nanoparticles and carbon nanotubes and methods of fabricating. The nanomaterials are provided within relatively low weight fractions, for example in the range of approximately 0.01 to about 0.4% by weight and distributed within the matrix by a magnetic mixing procedure to provide substantially uniform reinforcement of the nanocomposites. Advantageously, these nanocomposites provide significantly enhanced tensile strength, strain to failure, and fracture toughness over corresponding neat matrices.Type: GrantFiled: February 9, 2010Date of Patent: January 25, 2011Assignee: University of HawaiiInventors: Mohammad Naghi Ghasemi Nejhad, Vinod P Veedu, Andrea Yuen, Davood Askari
-
Patent number: 7875294Abstract: The present invention provides a method of attenuating the formation or reducing the severity of a bruise in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of bruising.Type: GrantFiled: September 28, 2006Date of Patent: January 25, 2011Assignee: Sessions Pharmaceuticals Inc.Inventors: Robert W. Sessions, Roger Sessions, legal representative, Alan R. Kahn
-
Publication number: 20100316718Abstract: The present invention relates to an activated foam made of a natural or synthetic rubber or a synthetic resin, characterized in that the foam contains a zirconium compound and/or a germanium compound, and has a closed-cell structure, wherein the foam is used so as to directly or indirectly contact with a human body when a pharmaceutical agent is administered. The activated foam can be directly or indirectly contacted with a human body to facilitate blood circulation and promote the improvement of physical condition and the cure of diseases. It also has no adverse effect.Type: ApplicationFiled: August 12, 2010Publication date: December 16, 2010Inventor: Tomizo Yamamoto
-
Patent number: 7838477Abstract: The present disclosure generally relates to cleansing products for cleansing the skin and hair. More particularly, the present disclosure relates to liquid cleansing compositions that have a sufficient viscosity to maintain particles suspended in the cleanser, but that may also be used with suitable dispensers, such as pump foam dispensers, to generate foam.Type: GrantFiled: August 24, 2006Date of Patent: November 23, 2010Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Scott W. Wenzel, Corey Cunningham, Julie M. Utschig
-
Publication number: 20100291179Abstract: The present invention relates to a composite biomaterial and a process for producing a composite biomaterial with controlled release of active ingredients, comprising a three-dimensional polymer-based support structure, and a polymer-based matrix structure. The active ingredients are in this case incorporated into the composite biomaterial via the matrix structure, and the composite biomaterial is obtainable by introducing the matrix structure into the support structure. The active ingredients may in this case be incorporated for example adhesively, via specific binder molecules or via enzyme-labile linker molecules via the matrix structure into the composite biomaterial.Type: ApplicationFiled: April 16, 2010Publication date: November 18, 2010Inventors: Dieter Stoll, Reinout Stoop, Juliana Vaz Nürnberger, Christoph Gaissmaier, Michael Ahlers, Claudia Bohnsack
-
Publication number: 20100291245Abstract: A soft, chewable and orally dissolvable and/or disintegrable product includes a biopolymer-sugar based matrix and botanical powder dispersed throughout the biopolymer-sugar based matrix. The biopolymer-sugar based matrix includes at least one biopolymer, at least one sugar and optional additives. Soft, chewable and orally dissolvable and/or disintegrable product can also include flavor beads.Type: ApplicationFiled: December 8, 2009Publication date: November 18, 2010Applicant: Philip Morris USA Inc.Inventors: Feng Gao, Shalva Gedevanishvili, Shengsheng Liu, Munmaya K. Mishra, William R. Sweeney, Randall Baren, Qinglin Li, Darin Colassaco, Salem Chouchane
-
Publication number: 20100285125Abstract: The present invention relates to an oral drug delivery system for poorly soluble drugs, which can provide sustained near zero order release of poorly water soluble drugs from erodible matrix systems. Erodible matrix core is prepared using at least one active and erosion modulators in a matrix of low molecular weight and high molecular weight hydrophilic polymers in combination with a pH sensitive polymer which enable uniform hydration, controlled erosion and pH independent drug release through out GIT. The core optionally contains solubilizers. The core is optionally coated using combination of low molecular weight water soluble and water insoluble polymers, plasticizer and fillers, which provides for drug release, following a lag time, which also helps to reduce food effects in the stomach.Type: ApplicationFiled: May 7, 2010Publication date: November 11, 2010Inventors: Padma Venkitachalam Devarajan, Joshi Vishvesh Mahendrakumar, Krishna Vishnupad
-
Publication number: 20100260835Abstract: A pharmaceutical composition comprising a moulded body of a polymer matrix, said polymer matrix comprising at least one polyaphron dispersion and at least one pharmaceutically active agent dispersed therein.Type: ApplicationFiled: June 26, 2008Publication date: October 14, 2010Inventors: Derek Alfred Wheeler, David Fraser Steele
-
Publication number: 20100215724Abstract: A nanotube device comprises a gel matrix that includes microcapsules and functionalized nanotubes, or other functionalized nanostructures incorporated into said gel matrix. Pharmaceutical compositions and methods of treatment comprising same. The pharmaceutical compositions of the present invention enable the specific and targeted delivery of therapeutic agents such as DNA molecules, peptides, including antibodies, drug molecules (e.g. small organic molecules), while offering sufficient resistance towards mucus layer of the intestine and high concentrations of enzymes and other molecules found in the blood stream and the GI tract.Type: ApplicationFiled: November 22, 2006Publication date: August 26, 2010Inventors: Satya Prakash, Hongmei Chen, Pavan Raja, Omkaram Nalamasu, Pulickel M. Ajayan
-
Publication number: 20100183688Abstract: A microparticle delivery system for an active compound which includes an active compound loaded onto polymeric microparticles, wherein the loaded microparticles are encased by a matrix material comprising about 68% to about 99%, by weight, of the microparticle delivery system. Compositions containing the microparticle delivery system, and methods of manufacturing the microparticle delivery system, also are disclosed.Type: ApplicationFiled: July 23, 2007Publication date: July 22, 2010Applicant: Amcol International CorporationInventors: Limin Liu, Ralph Spindler, Stephen J. Urbanec, Gholam-Reza Vakili-Tahami, Ashoke K. Sengupta, Kevin Cureton
-
Patent number: 7749539Abstract: Poly(ester-anhydrides) or polyesters formed from ricinoleic acid and natural fatty diacids and their method of preparation and its use for delivering bioactive agents including small drug molecules, peptides and proteins, DNA and DNA complexes with cationic lipids or polymers or nano and microparticles loaded with bioactive agents are disclosed herein. The drug delivery compositions are administered to a patient in a liquid form, increase in viscosity in vivo to form a drug depot or implant, and are able to release the incorporated bioactive agent for weeks. In the preferred embodiment, the drug delivery formulations are administered by injection. In one embodiment, the compositions are suitable for local or regional delivery of drugs to diseased sites, such as treating solid tumors and bone infections.Type: GrantFiled: January 23, 2004Date of Patent: July 6, 2010Assignee: Efrat Biopolymers Ltd.Inventor: Abraham J. Domb
-
Publication number: 20100151013Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.Type: ApplicationFiled: February 19, 2010Publication date: June 17, 2010Inventors: Anders Pettersson, Christer Nyström, Yvonne Hakansson
-
Publication number: 20100151028Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.Type: ApplicationFiled: December 17, 2009Publication date: June 17, 2010Applicant: Grunenthal GmbHInventors: Judy Ashworth, Elisabeth Arkenau-Maric, Johannes Bartholomäus, Heinrich Kugelmann
-
Patent number: 7727552Abstract: A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.Type: GrantFiled: March 26, 1998Date of Patent: June 1, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Koji Ukai, Tsutomu Hrada, Yasuyuki Suzuki
-
Patent number: 7713551Abstract: Disclosed is a solid or semi-solid gelatin nanoparticulate active agent dosage form comprising at least one nanoparticulate active agent and at least one gel forming substance which exhibits gelation sufficient to retain excess water in the solid or semi-solid gelatin form. The active agent particles have an effective average diameter prior to inclusion in the dosage form of less than about 2000 nm. The dosage form of the invention has the advantages of easy administration combined with rapid dissolution of the active agent following administration.Type: GrantFiled: September 11, 2003Date of Patent: May 11, 2010Assignee: Elan Pharma International Ltd.Inventors: Simon L. McGurk, David A. Czekai
-
Patent number: 7709005Abstract: The present invention provides a method of attenuating the formation or reducing the severity of neurogenic swelling and/or neurogenic inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic swelling and/or neurogenic inflammation.Type: GrantFiled: September 29, 2006Date of Patent: May 4, 2010Assignee: Sessions Pharmaceuticals Inc.Inventors: Robert W. Sessions, Alan R. Kahn
-
Publication number: 20100074955Abstract: The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.Type: ApplicationFiled: September 18, 2007Publication date: March 25, 2010Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Helmut Heinrich Buschmann, Xavier Codony-Soler
-
Patent number: 7666396Abstract: A single-use lip treatment product is disclosed. The single-use lip treatment product comprises a moisturizer and dissolves rapidly when applied to the lips providing a moisturizing benefit to the lips.Type: GrantFiled: September 11, 2003Date of Patent: February 23, 2010Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Beth A. Lange, Duane Krzysik, Jennifer Marvin, Mike Brunner
-
Patent number: 7662777Abstract: A method for the treatment and/or prevention of mucositis due to an antitumour treatment which comprises the administration of a composition containing suiglicotide to a patient in needs of said antitumour treatment.Type: GrantFiled: May 12, 2005Date of Patent: February 16, 2010Assignee: Gentium SpAInventors: Massimo Iacobelli, Laura Iris Ferro
-
Patent number: 7658942Abstract: The present invention relates to pre-formed devices for delivering benefit agents to the skin, hair or nails. The devices are patches or masks for cosmetic or therapeutic use and comprise a unilamellar, solid gel sheet having at least one surface at least partially coated with a discrete coating composition comprising at least one benefit agent for the skin, hair or nails. The invention also encompasses methods of producing and using such devices. The coating composition allows more efficient delivery of benefit agents to the skin than previously known devices and/or affords greater formulation flexibility.Type: GrantFiled: October 10, 2002Date of Patent: February 9, 2010Assignee: The Procter & Gamble CompanyInventors: George Endel Deckner, Delyth Myfanwy Jenkins, Kenneth Eugene Kyte, Michael Jude LeBlanc, Jennifer Elizabeth Phillips
-
Publication number: 20100028434Abstract: The present invention relates a biopolymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises: an acidic water-based medium, 0.1 to 10% by weight of a pH-gelling acid-soluble biopolymer; and 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and a pKa between 6.0 and 8.4. The liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid and homogeneous gel within a temperature range from 10 to 70° C. The present invention also relates to a method for preparing the composition and uses thereof.Type: ApplicationFiled: October 9, 2009Publication date: February 4, 2010Applicant: BIO SYNTECH CANADA, INC.Inventors: Abdellatif Chenite, Cyril Chaput, Dong Wang, Amine Selmani
-
Publication number: 20090324714Abstract: A dual adhesive layer dosage form for delivery of active agent to and across, the mucosa is disclosed. Particularly, bioadhesive tablets for administration at the vaginal mucosa are disclosed as having a central active layer sandwiched between two bioadhesive layers.Type: ApplicationFiled: June 26, 2009Publication date: December 31, 2009Applicant: WYETHInventors: Xiuying LIU, John KRESEVIC
-
Publication number: 20090297597Abstract: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers ticlopidine in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such multiparticulate modified release composition, and to methods for inhibiting platelet aggregation, inhibiting blood clotting, and reducing risk of stroke in a patient.Type: ApplicationFiled: June 9, 2006Publication date: December 3, 2009Inventors: Gary Liversidge, Scott Jenkins, Paul Stark, Niall M.N. Fanning, Gurvinder Singh Rekhi, John G. Devane
-
Patent number: 7625585Abstract: The present invention provides a method of attenuating the formation or reducing the severity of a neurogenic bruise in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of bruising.Type: GrantFiled: May 25, 2006Date of Patent: December 1, 2009Assignee: Sessions Pharmaceuticals Inc.Inventors: Robert W. Sessions, Alan R. Kahn
-
Publication number: 20090258060Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.Type: ApplicationFiled: June 24, 2009Publication date: October 15, 2009Inventors: Gary W. Cleary, Shoreh Parandoosh, Mikhail M. Feldstein, Anatoly E. Chalykh, Nicolai A. Plate, Valery G. Kulichikhin
-
Publication number: 20090214604Abstract: The invention relates to a method of obtaining hydrogels based on (i) cyclodextrins, (ii) cyclodextrins and cellulose ethers or (iii) cyclodextrins and guar gum or the derivatives of same, using molecules containing two or more glycidyl ether groups in the structure thereof as a cross-linking agent. The invention also relates to the compositions thus obtained, which can include active substances and pharmaceuticals and which form inclusion complexes with cyclodextrins. The invention further relates to the use of same as components of controlled-release devices, such as transdermal pharmaceutical forms, vaginal, otic, ocular, rectal, oral or buccal transmucosal forms and parenteral implants, which are designed to administer active substances or pharmaceuticals to humans, animals or plants, or as components of cosmetic formulations.Type: ApplicationFiled: February 15, 2006Publication date: August 27, 2009Applicant: Universidade De Santiago De CompostelaInventors: Carmen Alvarez Lorenzo, Carmen Rodriguez-Tenreiro Sanchez, Juan Jose Torres Labandeira, Angel Concheiro Nine
-
Publication number: 20090130213Abstract: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, or less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.Type: ApplicationFiled: October 31, 2007Publication date: May 21, 2009Inventors: Rajeev A. Jain, Stephen B. Ruddy, Kenneth lain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
-
Publication number: 20090053307Abstract: A pharmaceutical composition comprising a camptothecin as active ingredient is herein described. In particular immediate-release therapeutic systems are described for the improved oral absorption of 7-[(E)-t-butyloxyminomethyl] camptothecin, comprising a matrix consisting of liquid amphiphilic substances or having a melting point lower than 60° C., in which the active principle is at least partially dissolved and/or dispersed and/or inglobated.Type: ApplicationFiled: July 11, 2006Publication date: February 26, 2009Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE IUNITE S.P.A.Inventors: Antonio Longo, Silvia Pace, Massimo Pedrani
-
Publication number: 20090022780Abstract: The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds.Type: ApplicationFiled: January 31, 2007Publication date: January 22, 2009Applicant: EURO-CELTIQUE S.A.Inventors: Sabine Scherer, Christian Wagner, Christian Leuner, Wolfgang Fleischer
-
Publication number: 20090017120Abstract: A lecithin organogel composition used to deliver pharmaceutical products transdermally as well as a method for producing the lecithin organogel composition, which may contain up to 40% additive ingredients. Preferred embodiments of the invention may include lecithin organogel compositions which provide high penetrating power, which are ready-to-use, which have improved stability, which have a high uptake capacity for active drugs, and which do not grow mold if the gel becomes contaminated.Type: ApplicationFiled: March 13, 2008Publication date: January 15, 2009Applicant: Humco Holding Group, Inc.Inventors: John Olin Trimble, Christopher Michael Brisco
-
Publication number: 20090011024Abstract: A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.Type: ApplicationFiled: July 8, 2008Publication date: January 8, 2009Inventors: Walter C. Babcock, William J. Curatolo, Dwayne T. Friesen, Rodney J. Ketner, Julian B. Lo, James A.S. Nightingale, Ravi M. Shanker, James B. West
-
Patent number: 7452546Abstract: One or more agricultural active ingredients (such as fungicides or insecticides) are entrapped in polymeric matrixes to form particles having a diameter in the range from about 0.2 to about 200 microns. The particles are applied to soil, to seeds, or to plants and release the active ingredient(s) at a rate sufficiently low to avoid phytoxicity but at a rate sufficiently high to provide effective amounts of the active ingredient(s), preferably throughout the growing period of the plant.Type: GrantFiled: March 31, 2006Date of Patent: November 18, 2008Assignee: Monsanto Technology LLCInventors: M. Francis Botts, Frank C. Kohn, Maria L. Miller
-
Publication number: 20080220064Abstract: The present invention provides extended-release matrix formulations comprising a therapeutically effective amount of morphine or salt thereof, one or more hydrophilic controlled release polymers and one or more pharmaceutically acceptable excipients. The formulations provide extended release of morphine or salt thereof over a specified period of time after oral administration in humans or animals.Type: ApplicationFiled: December 6, 2007Publication date: September 11, 2008Inventors: Ketkar Anant RAMESH, Pratik Kumar, Ashok Rampal
-
Publication number: 20080206334Abstract: The present invention is directed to a controlled-release pharmaceutical composition providing a sustained delivery of the basic drug Terbutaline sulfate, said composition comprising at least Terbutaline sulfate or a derivative thereof as an active agent, and further comprising an inactive matrix, said matrix comprising a hydrophilic polysaccharide polymer mixture, said mixture comprising chitosan or a derivative thereof, and further comprising xanthan gum or a derivative thereof, wherein the ratio of xanthan gum and chitosan within said mixture is in the range from about 1:10 to about 10:1, and said composition optionally comprising sodium bicarbonate.Type: ApplicationFiled: December 29, 2005Publication date: August 28, 2008Inventors: Mayyas Al-Remawi, Adnan Badwan
-
Patent number: 7417021Abstract: A biologically active conjugate is disclosed comprising a biopolymer and a therapeutic agent joined by a disulfide bond. The conjugate, when formulated in a pharmaceutical composition with a suitable carrier, has improved in vivo stability and activity, and can be targeted to a variety of cells, tissues and organs.Type: GrantFiled: May 7, 2004Date of Patent: August 26, 2008Assignee: Genzyme CorporationInventors: Pericles Calias, Robert J. Miller
-
Patent number: 7413747Abstract: A transdermal therapeutic system (TTS) comprises a silicone-based polymer adhesive system having distributed therein (?)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol free base in an amount of about 5% to 40% by weight. The adhesive system comprises a silicone adhesive and an additive having increased solubility for the active substance, in an amount effective to increase dissolving capacity of the matrix for the active substance.Type: GrantFiled: October 31, 2007Date of Patent: August 19, 2008Assignees: LTS Lohmann Therapie-Systeme AG, Schwarz Pharma LimitedInventors: Walter Mueller, James V. Peck
-
Publication number: 20080181941Abstract: Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.Type: ApplicationFiled: August 17, 2007Publication date: July 31, 2008Applicant: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Mark Chasin
-
Publication number: 20080181951Abstract: We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5-40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described.Type: ApplicationFiled: January 22, 2008Publication date: July 31, 2008Applicant: AMERICAN SILVER, LLCInventors: Robert J. HOLLADAY, Herbert CHRISTENSEN, William D. MOELLER
-
Publication number: 20080146109Abstract: The present invention relates to a laminate prepared in part from a continuous acid polysaccharide film. In various embodiments, the laminate is useful for fabrication as a protective article as it typically is largely impermeable to hazardous chemical and biological agents, but is sufficiently permeable to water vapor that, if worn as protective apparel, it is both protective and comfortable to wear.Type: ApplicationFiled: December 15, 2006Publication date: June 19, 2008Applicant: E. I. DUPONT DE NEMOURS AND COMPANYInventors: EDWARD GEORGE HOWARD, NICOLE M. REINARTZ, RACHEL KAHN, RONALD JAMES MCKINNEY
-
Patent number: 7374774Abstract: The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more natural materials, one or more synthetic materials, or a combination thereof. The substance can be one or more therapeutic or cosmetic substances or other compounds, molecules, cells, vesicles. The compositions can be used in substance delivery, including drug delivery within an organism by, for example, releasing substances or containing cells that release substances. The compositions can be used for other purposes, such as prostheses or similar implants.Type: GrantFiled: September 22, 2003Date of Patent: May 20, 2008Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson
-
Publication number: 20080095848Abstract: The present invention relates to dry delivery system comprising a xerogel or film with applied active ingredients for topical active ingredient delivery or other purposes. Said delivery system are obtainable by a method according to the invention. The present invention also provides for methods for achieving defined localization of stable or unstable active substances on dry xerogels or films, which can be reconstituted into hydrogels. From the obtained delivery systems, the active substances are released with advantageous release kinetics.Type: ApplicationFiled: March 3, 2005Publication date: April 24, 2008Applicant: Ludwig-maximilian-UniversityInventors: Anke Stabenau, Gerhard Winter, Roland Schmidt
-
Publication number: 20080095847Abstract: Compositions, methods of fabrication and methods of treatment for the controlled release of a therapeutic substance to a treatment region are disclosed herein. In some embodiments, block copolymer-based release platforms (modified or unmodified) can be used to deliver a therapeutic substance to an inflamed site in, for example, the coronary tree or the kidney glomeri. The platforms can be carriers of at least one therapeutic substance. An external “trigger”, or stimulus, such as radiation, ultrasound, temperature, a magnetic field, a change in pH, a change in ionic strength or release of an enzyme, can be used to destabilize the platform in order to release its payload in a controlled manner once at a treatment site. Delivery devices can include a syringe, an infusion catheter, a porous balloon catheter, a double balloon catheter and the like.Type: ApplicationFiled: October 18, 2006Publication date: April 24, 2008Inventors: Thierry Glauser, Dariush Davalian, Florian Niklas Ludwig, Mikael Trollsas